- ¥13bn
- ¥10bn
- ¥2bn
- 88
- 16
- 16
- 33
Annual balance sheet for StemCell Institute, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 3,025 | 2,743 | 3,511 | 3,324 | 2,846 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 278 | 344 | 593 | 1,137 | 1,584 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,348 | 3,150 | 4,178 | 4,545 | 4,515 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 106 | 577 | 648 | 648 | 665 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,565 | 3,958 | 5,216 | 5,812 | 6,543 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,302 | 2,589 | 3,052 | 3,432 | 3,760 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2,305 | 2,636 | 3,112 | 3,513 | 3,850 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 1,260 | 1,322 | 2,104 | 2,299 | 2,693 |
| Total Liabilities & Shareholders' Equity | 3,565 | 3,958 | 5,216 | 5,812 | 6,543 |
| Total Common Shares Outstanding |